Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue

Area of Science:

• Metabolic Syndrome
• Endocrinology
• Pharmacology

Background:

• Fenofibrate is a peroxisome proliferator-activated receptor-α (PPARα) agonist used for dyslipidemia and insulin resistance.
• Vaspin is an adipocytokine linked to obesity and insulin resistance.
• The molecular mechanisms of fenofibrate's action require further elucidation.

Purpose of the Study:

• To investigate the effect of fenofibrate on serum vaspin levels in dyslipidemic patients.
• To explore the impact of fenofibrate on vaspin expression in adipose tissue and its correlation with insulin sensitivity in obese rats.
• To determine if fenofibrate directly influences vaspin expression in adipocytes.

Main Methods:

• Clinical study involving dyslipidemic patients treated with fenofibrate.
• In vivo study using obese rats treated with fenofibrate, analyzing vaspin mRNA and protein in different adipose tissues.
• In vitro study using 3T3-L1 adipocytes treated with fenofibrate.

Main Results:

• Fenofibrate treatment significantly increased serum vaspin levels in dyslipidemic patients, correlating with reduced body weight and enhanced insulin sensitivity.
• In obese rats, fenofibrate upregulated vaspin mRNA and protein in visceral adipose tissue (retroperitoneal, mesenteric, periepididymal) but not subcutaneous adipose tissue, correlating with improved insulin sensitivity.
• Fenofibrate treatment increased vaspin mRNA and protein expression in 3T3-L1 adipocytes.

Conclusions:

• Fenofibrate upregulates vaspin expression in dyslipidemic human subjects.
• Increased vaspin expression in visceral adipose tissue may be a key mechanism by which fenofibrate improves insulin sensitivity.
• Fenofibrate's action on vaspin warrants further investigation for its role in metabolic health.